Key Points {#FPar1}
==========

We conducted a comprehensive analysis of pooled data from seven randomized, double-blinded, placebo-controlled clinical trials of dupilumab (with or without concomitant topical corticosteroids) in adults with atopic dermatitis.Dupilumab treatment does not increase infection risk overall and is associated with lower rates of serious or severe infections and lower rates of non-herpetic skin infections, compared with placebo.Rates of herpesviral infections are slightly higher with dupilumab, mostly those due to oral herpes, but clinically important herpesviral infections, such as herpes zoster and eczema herpeticum, are lower with dupilumab than placebo.

Introduction {#Sec1}
============

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease characterized by skin barrier dysfunction, including imbalance of the skin microbiome, and immune dysregulation primarily skewed toward type 2 activity \[[@CR1], [@CR2]\]. Reduced expression of antimicrobial peptides and alterations in the skin microbiome, including *Staphylococcus aureus* colonization, contribute to AD pathobiology \[[@CR3]--[@CR5]\].

Patients with AD are at increased risk of serious bacterial skin infections and viral skin infections, including eczema herpeticum, eczema vaccinatum, and eczema coxsackium \[[@CR5]--[@CR17]\] and, compared with the general population, are at increased risk of serious extracutaneous and systemic infections \[[@CR17]--[@CR19]\].

Dupilumab, a fully human monoclonal antibody derived by proprietary technologies \[[@CR20], [@CR21]\], blocks the shared receptor component for interleukin-4 (IL-4) and IL-13, thus inhibiting signaling of both IL-4 and IL-13. Dupilumab is approved for subcutaneous (SC) administration at 300 mg every 2 weeks (q2w) for the treatment of patients 12 years and older in the USA with moderate-to-severe AD inadequately controlled with topical prescription therapies or when those therapies are not advisable \[[@CR22]\], for the treatment of adult AD patients not adequately controlled with existing therapies in Japan \[[@CR23]\], and for use in adults with inadequately controlled, moderate-to-severe AD who are candidates for systemic therapy in the European Union \[[@CR24]\]. Dupilumab is also approved by the US Food and Drug Administration \[[@CR22]\] as an add-on maintenance treatment in patients with moderate-to-severe asthma aged ≥ 12 years with an eosinophilic phenotype or with oral corticosteroid-dependent asthma, regardless of eosinophilic phenotype \[[@CR25]--[@CR27]\]. In addition, dupilumab treatment has significantly improved signs and symptoms and had an overall favorable safety profile in clinical trials in other type 2 immune diseases, including chronic rhinosinusitis with nasal polyposis (CRSwNP), and eosinophilic esophagitis, thus demonstrating the importance of IL-4 and IL-13 as drivers of multiple type 2 atopic/allergic diseases \[[@CR28], [@CR29]\].

Immunomodulatory agents, such as anti-tumor necrosis factor (anti-TNF) agents, anti-IL-23, anti-IL-17, and Janus kinase (JAK) inhibitors, increase the risk of infections \[[@CR30]--[@CR46]\]. However, in clinical trials with dupilumab, there was no evidence of an increase in overall infection rates, nor was there evidence of increased risk of serious or opportunistic infections in dupilumab-treated patients \[[@CR25]--[@CR29], [@CR47]--[@CR53]\]. Moreover, in clinical trials of dupilumab in patients with moderate-to-severe AD, dupilumab-treated patients have shown trends toward lower rates of bacterial and other non-herpetic skin infections and lower rates of the clinically important herpesviral infections eczema herpeticum and herpes zoster, but slightly higher rates of herpes simplex viral infections (i.e., non-eczema herpeticum or herpes zoster) compared with placebo \[[@CR47]--[@CR52]\].

Because pooling data from multiple clinical trials increases the likelihood of identifying and confirming signals from individual studies, we conducted a comprehensive analysis of pooled data from randomized, placebo-controlled, double-blinded, phase II and phase III clinical trials with treatment periods of 12--52 weeks to further evaluate the incidence of infections in studies of dupilumab in patients with AD. The objective of this pooled analysis was to assess infection rates for two regimens of dupilumab (SC 300 mg weekly \[qw\] or 300 mg q2w), compared with placebo, in adult patients with moderate-to-severe AD.

Methods {#Sec2}
=======

Studies {#Sec3}
-------

This pooled analysis included data from seven phase II and phase III randomized, placebo-controlled, double-blinded studies of dupilumab in adults with moderate-to-severe AD (R668-AD-1117, LIBERTY AD EVALUATE, R668-AD-1021, LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS, and LIBERTY AD CAFÉ) \[[@CR47]--[@CR52]\]. Detailed study designs are provided in the respective publications and are summarized in Table E1 in the Electronic Supplementary Material (ESM).

The analyses included all patients who received at least one dose of study drug (SC dupilumab 300 mg qw, 300 mg q2w, or placebo). Patients were categorized in treatment groups based on the treatment received (safety analysis set).

Endpoints {#Sec4}
---------

The endpoints used in this study are described in Table E2 in the ESM and include infections overall, infections leading to permanent discontinuation of study drug, serious or severe infections, non-herpetic skin infections, non-skin infections, and herpesviral infections. The definitions of the endpoints are based on reports of treatment-emergent adverse events (TEAEs) made during the treatment period of the clinical trials and are described according to the system organ class, high-level term (HLT), and preferred term (PT) of the version of the Medical Dictionary for Regulatory Activities (MedDRA) used in the respective study.

Assessments and Statistical Analyses {#Sec5}
------------------------------------

Events per 100 patient-years (PY) and patients with at least one event per 100 PY were assessed during the study treatment period.

Exposure-adjusted rates were used to compare dupilumab treatment (300 mg qw, 300 mg q2w, and combined qw + q2w) with placebo, and *p* values were obtained from a time-to-event exponential regression model with treatment as the only covariate. There was no apparent dose--response relation for infections with the dupilumab qw and q2w regimens, so statistical comparison of dupilumab versus placebo was carried out using the dupilumab qw and q2w groups combined.

In addition, for the overall endpoints, the differences between dupilumab and placebo were described separately for the monotherapy studies (R668-AD-1117, EVALUATE, R668-AD-1021, SOLO 1, and SOLO 2) and studies of dupilumab that required concomitant topical corticosteroids (TCS) (CHRONOS and CAFÉ) by using exposure-adjusted rates. Unless otherwise indicated, given the pooling of data from both monotherapy and concomitant therapy studies in the overall analyses, the terms "dupilumab" and "placebo" refer to the study treatments. Finally, numbers (percentage) of patients with 0, 1, 2, 3, 4, and \> 4 events of infections overall, serious or severe infections, non-herpetic skin infections, and herpesviral infections are provided using descriptive statistics.

Results {#Sec6}
=======

Patients {#Sec7}
--------

Data from 2932 patients were included in this analysis, of whom 1091 received placebo, 1095 dupilumab 300 mg qw, and 746 dupilumab 300 mg q2w.

Exposure-Adjusted Infection Rates {#Sec8}
---------------------------------

There were no significant differences between treatment groups in overall infection rates calculated either as the number of patients with at least one infection per 100 PY (Table [1](#Tab1){ref-type="table"}) or in the number of events per 100 PY (Table E3 in the ESM). Rates of events per 100 PY followed a trend similar to those seen for patients with at least one event per 100 PY. Approximately 129 patients per 100 PY in the placebo group had at least one infection, compared with approximately 126, 134, and 129 patients per 100 PY in the dupilumab 300 mg qw, 300 mg q2w, and combined groups, respectively. Similarly, there were approximately 155 infections per 100 PY in the placebo group and 150, 156, and 152 infections per 100 PY in the dupilumab 300 mg qw, 300 mg q2w, and combined groups, respectively. There were no apparent differences in infection rates between the dupilumab regimens.Table 1Exposure-adjusted numbers of patients with treatment-emergent infections during the study treatment periodPatients with ≥ 1 event, nP (nP/100 PY)Comparison with placebo, risk ratio (95% CI) *p* value^a^Placebo (*n* = 1091)Dupilumab 300 mg qw (*n* = 1095)Dupilumab 300 mg q2w (*n* = 746)Dupilumab combined (*n* = 1841)Dupilumab 300 mg qwDupilumab 300 mg q2wDupilumab combinedOverall453 (129.317)452 (126.486)287 (133.580)739 (129.149)0.98 (0.86, 1.11)0.741.03 (0.89, 1.20)0.671.00 (0.89, 1.12)0.98Infections leading to treatment discontinuation^b^5 (0.986)2 (0.382)1 (0.340)3 (0.367)0.39 (0.08, 2.00)0.260.35 (0.04, 2.95)0.330.37 (0.09, 1.56)0.18Serious or severe infections20 (3.978)7 (1.340)7 (2.393)14 (1.718)0.34 (0.14, 0.80)0.010.60 (0.25, 1.42)0.250.43 (0.22, 0.85)0.02Non-herpetic skin infections Skin structures and soft tissue infections^c^55 (11.255)23 (4.455)17 (5.867)40 (4.963)0.40 (0.24, 0.64)\< 0.0010.52 (0.30, 0.90)0.020.44 (0.29, 0.66)\< 0.001 Adjudicated skin infections^d^122 (26.563)69 (13.881)44 (15.672)113 (14.527)0.52 (0.39, 0.70)\< 0.0010.59 (0.42, 0.83)0.0030.55 (0.42, 0.71)\< 0.001Non-skin infections^e^424 (117.862)443 (122.416)281 (129.691)724 (125.141)1.04 (0.91, 1.19)0.581.10 (0.95, 1.28)0.211.06 (0.94, 1.20)0.33Herpesviral infections Total51 (10.379)57 (11.262)43 (15.243)100 (12.687)1.09 (0.74, 1.58)0.671.47 (0.98, 2.20)0.061.22 (0.87, 1.71)0.24 Clinically important (eczema herpeticum, herpes zoster)18 (3.590)3 (0.573)6 (2.054)9 (1.104)0.16 (0.05, 0.54)0.0030.57 (0.23, 1.44)0.240.31 (0.14, 0.68)0.004 Eczema herpeticum12 (2.380)2 (0.382)4 (1.368)6 (0.735)0.16 (0.04, 0.72)0.020.57 (0.19, 1.78)0.340.31 (0.12, 0.82)0.02 Herpes zoster7 (1.384)1 (0.191)2 (0.681)3 (0.367)0.14 (0.02, 1.12)0.060.49 (0.10, 2.37)0.380.27 (0.07, 1.03)0.055At each level of patient summarization, a patient is counted once if the patient reported ≥ 1 event. TEAEs included in the analysis were those that occurred during the study treatment period*CI* confidence interval, *HLT* MedDRA high-level term, *MedDRA* Medical Dictionary for Regulatory Activities, *nP* number of patients with ≥ 1 event, *nP/100 PY* number of patients with ≥ 1 event per 100 PY, *PY* patient-years, *q2w* every 2 weeks, *qw* weekly, *TEAE* treatment-emergent adverse event^a^*p* values are from a time-to-event exponential regression model with treatment as the only covariate^b^Infections that led to treatment discontinuation in the placebo group were cytomegalovirus infection, infected dermatitis, eczema herpeticum, bacterial endocarditis, molluscum contagiosum, sepsis, and septic embolus (1 case each; 1 patient who discontinued had 3 infectious TEAEs \[bacterial endocarditis, sepsis, and septic embolus\]). Infections that led to treatment discontinuation in the dupilumab group were conjunctivitis, eczema impetiginous, and folliculitis (1 case each)^c^MedDRA HLT^d^Excluding herpesviral infections; data not available for R668-AD-1117^e^Includes all infections other than those listed in the MedDRA HLT skin structures and soft tissue infections

Overall, a higher proportion of patients in the placebo group than in the dupilumab group discontinued for any reason (18.3% vs. 8.0%, placebo vs. dupilumab combined; 42.59 vs. 18.48 patients per 100 PY, respectively; *p* \< 0.0001). Very few patients permanently discontinued study treatment because of infections (five patients in the placebo group and three in the dupilumab groups combined), and there were no significant differences in discontinuation rates between treatment groups (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}a; and Table E3 in the ESM). Infections that led to treatment discontinuation in the placebo group were, by MedDRA PT, cytomegalovirus infection, infected dermatitis, eczema herpeticum, bacterial endocarditis, molluscum contagiosum, sepsis, and septic embolus (one case each; one patient who discontinued had three infectious TEAEs \[bacterial endocarditis, sepsis, and septic embolus\]). Infections that led to treatment discontinuation in the dupilumab groups were conjunctivitis, eczema impetiginous, and folliculitis (one case each).Fig. 1Exposure-adjusted numbers of patients with treatment-emergent infections during the study treatment period. **a** Infections leading to treatment discontinuation. **b** Serious or severe infections. At each level of patient summarization, a patient is counted once if the patient reported ≥ 1 event. Treatment-emergent adverse events included in the analysis were those that occurred during the study treatment period. *p* values are from a time-to-event exponential regression model with treatment as the only covariate. RRs for significant *p* values are shown in bold. *CI* confidence interval, *nP* number of patients with ≥ 1 event, *PY* patient-years, *q2w* every 2 weeks, *qw* weekly, *RR* risk ratio

Serious or severe infections were uncommon, but significantly less common in the dupilumab groups than in placebo, when assessed either as the number of patients per 100 PY (risk ratio \[RR\] 0.43, *p* = 0.02, dupilumab combined vs. placebo; Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}b) or as the number of events per 100 PY (RR 0.38, *p* = 0.004, dupilumab combined vs. placebo; Table E3 in the ESM).

Skin infections (non-herpetic) were significantly less common in the dupilumab groups than in the placebo group, whether assessed as MedDRA HLT (number of patients per 100 PY: RR 0.44, *p* \< 0.001, dupilumab combined vs. placebo) or as adjudicated skin infections (number of patients per 100 PY: RR 0.55, *p* \< 0.001, dupilumab combined vs. placebo; Fig. [2](#Fig2){ref-type="fig"}a and Table [1](#Tab1){ref-type="table"}; and Table E3 in the ESM). One patient each in the placebo and dupilumab qw groups had an ectoparasitic infection (acarodermatitis).Fig. 2Exposure-adjusted numbers of patients with treatment-emergent skin infections (non-herpetic) during the study treatment period. **a** Skin infections by HLT and adjudicated skin infections. **b** Adjudicated skin infections in monotherapy studies and studies with concomitant TCS. At each level of patient summarization, a patient is counted once if the patient reported ≥ 1 event. Treatment-emergent adverse events included in the analysis were those that occurred during the study treatment period. *p* values are from a time-to-event exponential regression model with treatment as the only covariate. RRs for significant *p* values are shown in bold. *CI* confidence interval, *HLT* MedDRA high-level term, *MedDRA* Medical Dictionary for Regulatory Activities, *nP* number of patients with ≥ 1 event, *PY* patient-years, *q2w* every 2 weeks, *qw* weekly, *RR* risk ratio, *TCS* topical corticosteroids. ^a^MedDRA HLT

Non-skin infections (i.e., excluding infections assessed as skin-structure or soft-tissue infections by MedDRA HLT) occurred at similar exposure-adjusted rates in the placebo and dupilumab groups (Table [1](#Tab1){ref-type="table"}; and Table E3 in the ESM). Common non-skin infections (MedDRA PTs) that were more frequent in the dupilumab groups combined than in the placebo group were nasopharyngitis, upper respiratory tract infection, conjunctivitis, oral herpes, and bacterial conjunctivitis; those that were more frequent in the placebo group than in the dupilumab groups combined included urinary tract infection, influenza, gastroenteritis, viral upper respiratory tract infection, and pharyngitis (Table [2](#Tab2){ref-type="table"}). Event rates (Table E4 in the ESM) were broadly similar to patient incidence rates (Table [2](#Tab2){ref-type="table"}).Table 2Treatment-emergent infections (by MedDRA PT) by incidence rate: number of patients per 100 PY (includes any PT reported in \> 5 patients in the placebo group, dupilumab 300 mg qw group, or dupilumab 300 mg q2w group)Infection (PT)Patients with infection, nP (nP/100 PY)Placebo (*n* = 1091)Dupilumab 300 mg qw (*n* = 1095)Dupilumab 300 mg q2w (*n* = 746)Dupilumab combined (*n* = 1841)Nasopharyngitis145 (31.378)155 (32.835)102 (38.178)257 (34.766)Upper respiratory tract infection62 (12.834)80 (16.254)30 (10.616)110 (14.198)Conjunctivitis10 (1.975)45 (8.732)33 (11.445)78 (9.705)Oral herpes17 (3.376)36 (7.033)27 (9.407)63 (7.886)Bacterial conjunctivitis9 (1.780)17 (3.289)10 (3.429)27 (3.339)Sinusitis16 (3.174)23 (4.493)4 (1.364)27 (3.354)Urinary tract infection24 (4.783)17 (3.283)10 (3.433)27 (3.337)Herpes simplex10 (1.975)11 (2.114)13 (4.475)24 (2.960)Influenza23 (4.600)15 (2.887)8 (2.748)23 (2.837)Gastroenteritis14 (2.788)13 (2.499)9 (3.085)22 (2.709)Viral upper respiratory tract infection16 (3.186)13 (2.516)6 (2.061)19 (2.352)Pharyngitis18 (3.565)12 (2.307)6 (2.047)18 (2.213)Rhinitis8 (1.579)13 (2.506)5 (1.712)18 (2.220)Bronchitis12 (2.373)9 (1.725)7 (2.394)16 (1.965)Cystitis5 (0.986)8 (1.535)4 (1.366)12 (1.474)Molluscum contagiosum3 (0.591)9 (1.734)2 (0.681)11 (1.353)Cellulitis13 (2.578)8 (1.537)2 (0.683)10 (1.230)Respiratory tract infection5 (0.985)7 (1.342)1 (0.340)8 (0.981)Tonsillitis3 (0.591)6 (1.149)2 (0.681)8 (0.981)Gastroenteritis viral8 (1.577)3 (0.574)4 (1.365)7 (0.858)Conjunctivitis viral2 (0.393)1 (0.191)5 (1.708)6 (0.735)Eczema herpeticum12 (2.380)2 (0.382)4 (1.368)6 (0.735)Furuncle8 (1.582)1 (0.191)5 (1.715)6 (0.736)Staphylococcal skin infection7 (1.382)3 (0.574)3 (1.025)6 (0.736)Otitis externa10 (1.980)3 (0.574)2 (0.681)5 (0.613)Herpes zoster7 (1.384)1 (0.191)2 (0.681)3 (0.367)Bacterial skin infection12 (2.374)2 (0.383)02 (0.245)At each level of patient summarization, a patient is counted once if the patient reported ≥ 1 event. TEAEs included in the analysis were those that occurred during the study treatment period*MedDRA* Medical Dictionary for Regulatory Activities, *nP* number of patients with ≥ 1 event, *nP/100 PY* number of patients with ≥ 1 event per 100 PY, *PT* MedDRA preferred term, *PY* patient-years, *q2w* every 2 weeks, *qw* weekly, *TEAE* treatment-emergent adverse event

Systemic or invasive infections were uncommon; of note, one patient in the dupilumab q2w group had, by MedDRA PT, bacterial sepsis, two patients in the placebo group had sepsis (including one who also had bacterial endocarditis and septic embolus, which led to treatment discontinuation, as noted above), and one patient in the placebo group had a moderate cytomegalovirus infection that led to treatment discontinuation, as noted above. There were no cases of endoparasitic (e.g., helminthic) infections.

Overall rates of herpesviral infections did not differ significantly between placebo and dupilumab groups when assessed as the number of patients with at least one event per 100 PY, but when assessed as the number of events per 100 PY, they were slightly more common in the dupilumab q2w group and the dupilumab groups combined than in the placebo group (Table [1](#Tab1){ref-type="table"}; and Table E3 in the ESM). The clinically important herpesviral infections eczema herpeticum and herpes zoster were both uncommon; eczema herpeticum was significantly more common in the placebo group than in the dupilumab qw or dupilumab combined groups, whether assessed as patients per 100 PY or events per 100 PY (Table [1](#Tab1){ref-type="table"}; and Table E3 in the ESM). The incidence of herpes zoster infection was numerically higher in the placebo group compared with the dupilumab groups (Table [1](#Tab1){ref-type="table"}; and Table E3 in the ESM). However, the combined rate of the clinically important herpesviral infections eczema herpeticum and herpes zoster was significantly higher in the placebo group than in the dupilumab qw group (RR 0.16, *p* = 0.003) or the dupilumab groups combined (RR 0.31, *p* = 0.004; Table [1](#Tab1){ref-type="table"}; and Table E3 in the ESM).

The overall patterns of infection in studies in which dupilumab was administered as monotherapy (R668-AD-1117, EVALUATE, R668-AD-1021, SOLO 1, and SOLO 2) or with concomitant TCS (CHRONOS and CAFÉ) were similar to those seen in the full analysis of pooled data: in both of these groups of studies there were similar rates of infections overall in the placebo and dupilumab groups, and higher rates of serious or severe infections, non-herpetic skin infections, and clinically important herpesviral infections (eczema herpeticum or herpes zoster) in the placebo groups than in the dupilumab groups (Tables E5 and E6 in the ESM). Skin infections were reported at higher rates in all treatment groups in the monotherapy studies than in the concomitant TCS studies (Fig. [2](#Fig2){ref-type="fig"}b).

Patients with Multiple Infections {#Sec9}
---------------------------------

There were no apparent differences between treatment groups in the percentages of patients with multiple (≥ 2 vs. 0 or 1) infections overall, skin infections, or herpesviral infections (Table E7 in the ESM). Multiple total infections were reported in similarly small proportions of patients in the placebo and dupilumab groups. One patient had two serious or severe infections and another had three such events; both patients were in the placebo group. More patients in the placebo group than in the dupilumab groups had two or more skin infections (whether assessed as the HLT skin structures and soft tissue infections or as adjudicated skin infections). Multiple herpesviral infections were reported in very small proportions of patients in the placebo group and in the dupilumab groups combined.

Anti-Infective Medications {#Sec10}
--------------------------

Concomitant systemic anti-infective medications were used significantly less by patients in the dupilumab groups than in the placebo group (RR 0.78, *p* = 0.002, dupilumab combined vs. placebo; Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Systemic anti-infective medication use. **a** Number of patients with ≥ 1 use of systemic anti-infective medication per 100 PY. **b** Systemic anti-infective medication use by number of events per 100 PY. RRs for significant *p* values are shown in bold. *CI* confidence interval, *nE* number of events, *nP* number of patients with ≥ 1 event, *PY* patient-years, *q2w* every 2 weeks, *qw* weekly, *RR* risk ratio

Discussion {#Sec11}
==========

In this pooled analysis, dupilumab- and placebo-treated patients did not significantly differ in their rates of overall infections or discontinuation due to infections, whereas serious or severe infections, skin infections, and clinically important herpesviral infections (eczema herpeticum or herpes zoster) occurred at lower rates in the dupilumab groups than in the placebo group. Fewer systemic anti-infectives were used in the dupilumab groups than in the placebo group. There were no differences in infection rates overall between dupilumab regimens. Pooling data from multiple studies increased the sample size and thereby increased the precision of the analysis, thus providing the opportunity to confirm or refute trends noted in individual studies and enhancing the ability to detect rare events. Outcomes of this pooled data analysis are consistent with those of the individual studies, and no new safety signals were detected \[[@CR47]--[@CR52]\].

In this pooled data analysis, dupilumab, compared with placebo, reduces rates of skin infections, consistent with the individual studies \[[@CR47]--[@CR52]\]; differences between the pooled groups were nominally statistically significant. The aggregate rate of skin infections in pooled placebo groups in this analysis are consistent with placebo-group rates in clinical trials of other therapies in similar populations \[[@CR54]\], reflecting the considerable burden of skin infections in moderate-to-severe AD. Skin infections are common in patients with AD and more so in patients with severe disease \[[@CR4], [@CR5], [@CR11]--[@CR13], [@CR54]--[@CR56]\]. Several aspects of the pathobiology of AD may increase patients' susceptibility to skin infections, including skin barrier dysfunction, skin damage associated with scratching, alterations in the skin microbiome, and a reduced expression of antimicrobial peptides \[[@CR4], [@CR11], [@CR55], [@CR56]\]. Impairment of the epidermal barrier function results in part from the overexpression of type 2 cytokines and imbalance of the skin microbiome \[[@CR56]\]. Therefore, the lower incidence of skin infections in dupilumab-treated patients compared with placebo-treated patients may be a result of several mechanisms, including dupilumab-mediated improvement of skin barrier function (either indirectly through inhibition of type 2 cytokines or directly through a reduction in mechanical damage to the skin caused by scratching) and favorable changes to the microbiome. Indeed, dupilumab reduces the abundance of *S. aureus* and increases microbial diversity on lesional and non-lesional skin in patients with AD \[[@CR57]\].

Rates of serious or severe infections were significantly lower in the dupilumab groups combined than in the placebo group, and there was no evidence of an increase in risk of opportunistic infections with dupilumab. Serious and severe infections were grouped on the basis that these categories probably overlap. Overall, rates of serious or severe infection were low in this analysis, especially compared with rates reported with immunosuppressive medications \[[@CR58]--[@CR61]\]. The risks of extracutaneous and invasive infections can be increased by systemic medications with a broad immunosuppressive effect, such as corticosteroids and non-steroidal immunosuppressants (e.g., cyclosporine, methotrexate, azathioprine, mycophenolates, and JAK inhibitors), medications that may be used in patients with moderate-to-severe AD (or are in development for AD) \[[@CR11], [@CR30], [@CR58], [@CR60], [@CR62], [@CR63]\].

Biologic agents that target the immunologic pathways associated with AD and other atopic diseases provide potentially more specific and effective therapeutic approaches than use of broad systemic immunosuppressants \[[@CR64], [@CR65]\]. However, in clinical experience, type 1 immunity-suppressing biologics in rheumatologic and dermatologic disorders are associated with an increased risk of infection in general, and with increased risks of serious extracutaneous and systemic infections such as tuberculosis, bacterial sepsis, opportunistic infections, and invasive fungal infections (e.g., histoplasmosis) \[[@CR31]--[@CR46], [@CR66]\]. These biologics are mainly TNF-α and IL-17 inhibitors and affect type 1 immune responses important in host immunity \[[@CR40], [@CR41]\]. Indeed, some biologics used to treat psoriasis have boxed warnings of the risk of serious infections, and many biologics, including TNF-α inhibitors (e.g., adalimumab, infliximab, etanercept, and certolizumab pegol), IL-17 inhibitors (secukinumab and ixekizumab), and IL-12/IL-23 inhibitors (ustekinumab and guselkumab), carry a requirement for patient testing for tuberculosis before use \[[@CR31]--[@CR38]\].

In contrast to other biologics, dupilumab targets the activity of IL-4 and IL-13, cytokines important in type 2 immune pathways, which are not crucial to host defense mechanisms against most infectious agents, except endoparasites, specifically intestinal helminths \[[@CR67]--[@CR70]\]. This analysis of pooled data from dupilumab studies revealed no parasitic infections other than one case each of ectoparasitic infection (acarodermatitis) in the placebo group and the dupilumab qw group; none of the studies included in this analysis reported tuberculosis infections or reactivations. Of note, dupilumab did not have an impact on T-cell- and B-cell-mediated (or non-T-cell-mediated) antibody response in a clinical trial using two non-live vaccines (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine; and quadrivalent meningococcal polysaccharide vaccine) \[[@CR50]\]. Direct evidence supporting the safety of administering live vaccines in patients treated with dupilumab is not yet available.

The overall incidence of total herpesviral infections was low in all groups. Herpesviral infection incidence rates overall were slightly higher in the dupilumab groups than in the placebo group, but the difference was small (\< 1%). Oral herpes (herpes labialis) accounted for most of the herpesviral infections. The molecular basis of herpes simplex viral reactivation is poorly understood, but the external triggers are fairly well characterized (e.g., sun exposure, stress) \[[@CR71]--[@CR73]\]. Notably, the incidences of eczema herpeticum and herpes zoster were higher in the placebo group than in the dupilumab groups. The higher rate of eczema herpeticum in the placebo group reflects the increased risk of this clinically important and dangerous herpesviral infection in patients with AD, an infection reported to occur in approximately 3% of patients with AD \[[@CR14]\]. Patients affected by eczema herpeticum tend to have type 2-dominant disease \[[@CR6]\], and the smaller number of events of this infection in the dupilumab groups is consistent with the mechanism of action of dupilumab, which inhibits signaling of IL-4 and IL-13, key drivers of type 2 immune diseases.

There were few differences between the dupilumab and placebo groups in the incidences of specific types of infectious disease as described by PTs. One exception was conjunctivitis, which was more common in dupilumab-treated patients than placebo-treated patients. However, the MedDRA PT "conjunctivitis" represents conjunctivitis of unspecified or undetermined etiology and defaults to the "Infections and Infestations" system organ class in MedDRA. Based on feedback from investigators through the data query process in these clinical trials, most of the adverse events coded as the PT "conjunctivitis" appeared to be non-infectious, but otherwise of unclear etiology. Indeed, there were no statistically significant differences between the dupilumab and placebo groups in the incidences of PT-defined conjunctivitis with specified bacterial or viral etiology. Current data indicate that dupilumab is associated with an increased incidence of conjunctivitis (all etiologies and clinical phenotypes combined) in patients with moderate-to-severe AD \[[@CR48]--[@CR52]\]; notably, no such increase was observed with dupilumab in studies of asthma \[[@CR25]--[@CR27]\] or CRSwNP \[[@CR28]\], suggesting that this phenomenon is specific to the AD setting. As a result, adverse events of conjunctivitis of undetermined etiology (PT "conjunctivitis") that were classified as infections by the default MedDRA coding pathway may have slightly inflated the rate of overall infections in this pooled analysis, mostly for dupilumab-treated patients. A detailed report of conjunctivitis adverse events in dupilumab clinical trials provides an in-depth analysis of these events \[[@CR74]\].

Dupilumab monotherapy studies and studies that required use of concomitant TCS had similar patterns of infection rates overall. In contrast, rates of skin infections were higher in all treatment groups in the monotherapy studies than in the studies that required concomitant TCS use, an observation suggesting that concomitant TCS provides a benefit additional to that of dupilumab in preventing skin infections, perhaps through incremental additional improvement in overall skin condition \[[@CR48]--[@CR52]\].

Multiple infections were uncommon. The placebo and dupilumab groups contained similar proportions of patients with multiple infections overall. In contrast, the placebo groups had higher proportions of patients with multiple skin infections, a finding consistent with higher overall rates of skin infections in the placebo group than in the dupilumab groups.

Meta-analyses of infections in dupilumab clinical trials have reported similar outcomes \[[@CR75], [@CR76]\]. However, compared with those meta-analyses, the present pooled analysis was more thorough, with full access to the clinical database and raw data, and thus was more robust, with more complete information than the previously published meta-analyses \[[@CR3], [@CR4]\], which were based only on published data.

Our analysis has some limitations. Although this pooled analysis provides data on a large number of patients, including a robust control group, there are also some limitations in this analysis, including those related to MedDRA terminology. A higher dropout rate in the placebo group may have resulted in an underestimation of infection rates, because it limited the opportunity to observe randomly occurring adverse events, including infections. Exposure-adjusted analyses mitigate, but do not completely remove, this bias in favor of placebo, particularly in the analysis of recurring events. This analysis was limited to randomized, placebo-controlled clinical trials, which enabled comparison of placebo- and dupilumab-treated patients, but the numbers of patients may still be too small to identify risks associated with rare events. As the population of patients treated with dupilumab increases over time, further data will become available on these risks. There were no endoparasitic infections (e.g., helminthic infections) reported in this analysis; however, the studies were conducted mostly in North America and Europe and did not include known endemic regions for parasites. Type 2 immunity is a key component of anti-helminthic host defense \[[@CR77], [@CR78]\], so further data are needed in patients from regions endemic for these types of parasitic infections. The results of our infection analyses used pooled data from the safety analysis sets and did not account for the effects of rescue medication, which was used by considerably more patients in the placebo group than in the dupilumab groups. In most cases, the rescue medication was TCS, which could potentially reduce the incidence of skin infections by reducing inflammation or altering the microbiome \[[@CR79]\]. On the other hand, TCS could exacerbate infections by inhibiting healing \[[@CR80]\]. This situation reflects real-world treatment paradigms, in which patients may receive additional medications to their baseline treatment in case of AD exacerbation. Because few patients received immunosuppressants as rescue medication, we did not perform subgroup analyses by immunosuppressant use; such subgroup analyses would have had a very small sample and therefore could not provide much insight into any additional impact of rescue immunosuppressant use on infection risk.

Conclusions {#Sec12}
===========

Rates of serious or severe infections and bacterial non-herpetic skin infections were significantly lower in the dupilumab groups compared with the placebo group, in this pooled analysis of data from phase II and phase III clinical trials of dupilumab. There was no significant difference between dupilumab and placebo groups in overall infection rates, and overall, there were no differences in infection rates between the dupilumab regimens. The dupilumab groups had lower use of systemic anti-infective medications than the placebo group. Overall, herpesviral infections were more common in the dupilumab 300 mg q2w and dupilumab groups combined, versus the placebo group, but the clinically more concerning eczema herpeticum and herpes zoster infections were less common with dupilumab than with placebo. The results of this analysis support the safety of dupilumab for the treatment of moderate-to-severe AD in adults, and the larger sample provided by pooling data showed no new safety signals.
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